183 related articles for article (PubMed ID: 30283800)
1. Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study.
Ren DF; Zheng FC; Zhao JH; Shen GS; Ahmad R; Zhang SS; Zhang Y; Kan J; Dong L; Wang ZY; Zhao FX; Zhao JD
World J Clin Cases; 2018 Sep; 6(10):373-383. PubMed ID: 30283800
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection.
Yu Y; Zhang Z; Meng Q; Ma Y; Fan X; Sun J; Wang G
Front Oncol; 2021; 11():684627. PubMed ID: 34109131
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients.
Yu S; Wang Y; Cheng X; Lv M; Cui Y; Li W; Yu Y; Li Q; Liu T
Cancer Manag Res; 2020; 12():10091-10101. PubMed ID: 33116865
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer.
Wang K; Yu Y; Zhao J; Meng Q; Xu C; Ren J; Zhang Y; Wang Y; Wang G
Curr Gene Ther; 2024; 24(2):147-158. PubMed ID: 37767800
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK;
Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
8. A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Zheng S; Zhou Y; Sun Y; Wang Z; Lu Y
Cancer Chemother Pharmacol; 2019 Oct; 84(4):819-827. PubMed ID: 31388724
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
Liang Y; Zhao L; Chen H; Lin T; Chen T; Zhao M; Hu Y; Yu J; Liu H; Li G
BMC Cancer; 2021 Feb; 21(1):196. PubMed ID: 33632161
[TBL] [Abstract][Full Text] [Related]
10. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of adjuvant immunotherapy (Tislelizumab) plus chemotherapy vs. adjuvant chemotherapy alone in lymph node-positive patients with gastric cancer after D2 radical resection: a prospective, 2-arm, phase II study.
Shi JW; Zhou Y; Wu S
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10472-10480. PubMed ID: 37975371
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis.
Tang C; Feng W; Bao Y; Chen C
Onco Targets Ther; 2020; 13():12661-12666. PubMed ID: 33324076
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
15. Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.
Liu X; Yan Y; Lu L; Liu Y; Ma J; Wang X; Wang D; Liu B; Liu Z; Zhou X; Cui H; Zhao Z; Li C; Liu J; Li W; Huang QX; Zhao Q; Liu T; Fu W
Cancer Med; 2024 Jun; 13(11):e7326. PubMed ID: 38826114
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer.
Yu Y; Zhang Z; Meng Q; Wang K; Li Q; Ma Y; Yao Y; Sun J; Wang G
J Gastric Cancer; 2022 Apr; 22(2):107-119. PubMed ID: 35534448
[TBL] [Abstract][Full Text] [Related]
19. [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
Ji J; Liang H; Zhan Y; Liu Y; He Y; Ye Y; Sun Y; Huang C; Yan M; Shi Y; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Feb; 17(2):133-8. PubMed ID: 24577767
[TBL] [Abstract][Full Text] [Related]
20. Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy.
Feng WM; Tang CW; Guo HH; Bao Y; Fei MY
Biomed Pharmacother; 2015 May; 72():140-3. PubMed ID: 26054688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
